NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Forecast, Price & News $0.60 0.00 (0.00%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$0.57▼$0.6350-Day Range$0.58▼$1.3552-Week Range$0.56▼$5.07Volume2.49 million shsAverage Volume1.66 million shsMarket Capitalization$106.27 millionP/E RatioN/ADividend YieldN/APrice Target$5.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sangamo Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside866.7% Upside$5.80 Price TargetShort InterestHealthy5.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingSelling Shares$3 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.84) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector289th out of 975 stocksBiological Products, Except Diagnostic Industry43rd out of 156 stocks 4.4 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.80, Sangamo Therapeutics has a forecasted upside of 866.7% from its current price of $0.60.Amount of Analyst CoverageSangamo Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.43% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 8.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 1.7 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,000,000.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions59.81% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to decrease in the coming year, from ($0.84) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sangamo Therapeutics (NASDAQ:SGMO) StockSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.Read More SGMO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comInsider Selling: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Major Shareholder Sells 6,000,000 Shares of StockSeptember 29, 2023 | benzinga.comSangamo Therapeutics 10% Owner Sold $3.00M In Company StockOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 8, 2023 | msn.comSangamo Therapeutics: Recent Updates Bolster My Long-Term ConvictionSeptember 4, 2023 | finance.yahoo.comRecent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past yearSeptember 2, 2023 | finance.yahoo.comUntapped Potential: 3 Stocks Tackling the Toughest Rare DiseasesAugust 15, 2023 | markets.businessinsider.comAnalyst Ratings for Sangamo TherapeuticsAugust 15, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Sangamo Therapeutics (SGMO) Buy RecommendationOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 15, 2023 | finance.yahoo.comTime To Worry? Analysts Are Downgrading Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) OutlookAugust 15, 2023 | finance.yahoo.comDoes This Valuation Of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Imply Investors Are Overpaying?August 14, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)August 11, 2023 | msn.comWedbush Maintains Sangamo Therapeutics (SGMO) Outperform RecommendationAugust 11, 2023 | msn.comWells Fargo Maintains Sangamo Therapeutics (SGMO) Overweight RecommendationAugust 8, 2023 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2023 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsAugust 8, 2023 | benzinga.comA Preview Of Sangamo Therapeutics's EarningsAugust 1, 2023 | finance.yahoo.comSangamo Therapeutics Announces Second Quarter 2023 Conference Call and WebcastJuly 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG)July 20, 2023 | finance.yahoo.comSangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic EditingJuly 19, 2023 | finance.yahoo.comThe past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitableJuly 18, 2023 | marketwatch.comSangamo Therapeutics Signs Virus Capsid Research Evaluation and Option Agreement With Eli Lilly's PrevailJuly 17, 2023 | markets.businessinsider.comSangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus CapsidsJuly 17, 2023 | finance.yahoo.comSangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered CapsidsJune 29, 2023 | markets.businessinsider.comSangamo Gets License To Combine Voyager TRACER Capsid With Sangamo's ZF-TRs To Treat Prion DiseaseJune 29, 2023 | finance.yahoo.comSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion DiseaseJune 15, 2023 | insidermonkey.com5 DNA Stocks Billionaires Are Loading Up OnSee More Headlines Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Company Calendar Last Earnings8/08/2023Today10/03/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees478Year Founded1995Price Target and Rating Average Stock Price Forecast$5.80 High Stock Price Forecast$10.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+866.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,280,000.00 Net Margins-90.86% Pretax Margin-93.50% Return on Equity-50.17% Return on Assets-30.62% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.97 Sales & Book Value Annual Sales$111.30 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.33Miscellaneous Outstanding Shares177,110,000Free Float171,799,000Market Cap$106.27 million OptionableOptionable Beta1.20 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Alexander D. Macrae Ch.B (Age 60)M.B., MRCP, Ph.D., CEO, Pres & Director Comp: $1.17MMs. Prathyusha Duraibabu CPA (Age 44)M.B.A., Sr. VP, CFO & Principal Accounting Officer Comp: $628.08kMr. D. Mark McClung (Age 60)Exec. VP & COO Comp: $710.3kDr. Jason D. Fontenot Ph.D. (Age 53)Sr. VP & Chief Scientific Officer Comp: $682.76kPhillip RamseyHead of Technical OperationsMs. Aron FeingoldHead of Corp. Communications & Investor Relations OfficerMr. Scott B. Willoughby (Age 48)Sr. VP, Gen. Counsel & Corp. Sec. Ms. Whitney JonesChief People OfficerDr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)Sr. VP & Chief Devel. Officer Dr. Lisa Rojkjaer M.D. (Age 57)Chief Medical Officer More ExecutivesKey CompetitorsCurisNASDAQ:CRISAgenusNASDAQ:AGENCentury TherapeuticsNASDAQ:IPSCTalaris TherapeuticsNASDAQ:TALSJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsBiogen Inc.Sold 6,000,000 sharesTotal: $3 M ($0.50/share)California State Teachers Retirement SystemSold 124,143 shares on 8/21/2023Ownership: 0.027%Nuveen Asset Management LLCSold 664,326 shares on 8/16/2023Ownership: 0.406%Goldman Sachs Group Inc.Bought 46,085 shares on 8/15/2023Ownership: 0.633%XTX Topco LtdBought 51,324 shares on 8/15/2023Ownership: 0.145%View All Insider TransactionsView All Institutional Transactions SGMO Stock - Frequently Asked Questions Should I buy or sell Sangamo Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SGMO shares. View SGMO analyst ratings or view top-rated stocks. What is Sangamo Therapeutics' stock price forecast for 2023? 7 equities research analysts have issued 12-month price objectives for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $10.00. On average, they anticipate the company's stock price to reach $5.80 in the next twelve months. This suggests a possible upside of 866.7% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts. How have SGMO shares performed in 2023? Sangamo Therapeutics' stock was trading at $3.14 on January 1st, 2023. Since then, SGMO stock has decreased by 80.9% and is now trading at $0.60. View the best growth stocks for 2023 here. When is Sangamo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our SGMO earnings forecast. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.02. The biopharmaceutical company had revenue of $6.84 million for the quarter, compared to analyst estimates of $22.33 million. Sangamo Therapeutics had a negative net margin of 90.86% and a negative trailing twelve-month return on equity of 50.17%. What ETFs hold Sangamo Therapeutics' stock? ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM). What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC). What is Sangamo Therapeutics' stock symbol? Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO." How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sangamo Therapeutics' stock price today? One share of SGMO stock can currently be purchased for approximately $0.60. How much money does Sangamo Therapeutics make? Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $106.27 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. How many employees does Sangamo Therapeutics have? The company employs 478 workers across the globe. How can I contact Sangamo Therapeutics? Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951. This page (NASDAQ:SGMO) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.